RIPK1 and osteonecrosis: Necrostatin-1 (NEC1) is a receptor-interacting protein kinase-1 (RIPK1)-targeted necroptosis inhibitor that has shown potential therapeutic effects in various skeletal system diseases, including cartilage thinning, osteonecrosis, osteoporosis, and OA (L. Cao and Mu, 2021).